Recruiting Clinical Trials

Displaying 21 - 30 of 227 result(s)
Study Title Condition Phase Location
A Participant and Investigator-blinded, Randomized, Placebo-controlled Phase 2a Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of TIN816 in Patients With Sepsis-associated Acute Kidney Injury Acute Kidney Injury Due to Sepsis Phase 2
  • Country: 
    Belgium
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting (VICTORION-Implement) Hypercholesterolemia Not Given
  • Country: 
    Germany
A Non-interventional Study Evaluating Kesimpta® (Ofatumumab) Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies [KAIROS] Multiple Sclerosis Not Given
  • Country: 
    Germany
Special Drug Use-results Surveillance of Scemblix Tablets (Resistant or Intolerant Chronic Myeloid Leukemia , CABL001A1401) Chronic Myeloid Leukemia Not Given
  • Country: 
    Japan
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study Breast Cancer Not Given
  • Country: 
    France
A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Br ... Asthma Phase 2
  • Country: 
    Bulgaria
  • Country: 
    Hungary
  • Country: 
    Poland
  • Country: 
A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) Primary Immune Thrombocytopenia Phase 3
  • Country: 
    Singapore
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome Myelodysplastic Syndromes Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan Prostate Cancer Phase 2
  • Country: 
    Japan
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments Advanced Solid Tumors Phase 1
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Canada
  • Country: